BioSpace News Archive

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the MELANI-01 trial has been placed on clinical hold by the U.S. Food and Drug Administration (FDA).

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics backed by The Carlyle Group, announced Joseph M. Busky has joined the Company as Chief Financial Officer, effective July 7, 2020.

BWX Technologies, Inc. (NYSE: BWXT) today announced that Martyn Coombs has been appointed president, BWXT ITG Canada, Inc. (BWXT ITG Canada), effective July 20, 2020.

Community-acquired pneumonia (CAP) has been a leading cause of mortality among people with infectious diseases and affects people of all age groups.

Hospital disinfectant products are used to kill or eliminate harmful agents such as virus, bacteria, and fungi from an equipment, floor, or patient’s skin and body.

The demand within the global hospital-acquired pneumonia prevention has been rising on account of the growing focus given on maintaining high standards of hygiene across hospitals.

Klebsiella pneumoniae infections are usually hospital acquired and patients with compromised defense mechanisms are more prone to these infections.

DLA Piper represented Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, in its acquisition of RareGen, LLC, a portfolio company of healthcare investment firm PBM Capital.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenues in the second fiscal quarter of 2020 to be in the range of $201 million to $202 million, an increase of approximately 86% - 87% over the prior year quarter.

The impact of malaria is serious and getting worse throughout the world.